The association of socioeconomic and clinical characteristics with health-related quality of life in patients with psoriasis: a cross-sectional study

Table 3 DLQI Scores by clinical factors in patients with psoriasis

Variables	No. of patients	DLQI Scores	p-value	DLQI ≤10		DLQI ≥11		p-value
Variables	No. of patients	Mean ± SD	p-value	N	(%)	N	(%)	p-value
Total participants	299	12.4 ± 7.6		138	(46.2)	161	(53.8)
Duration of psoriasis (years)
1–9	33	14.8 ± 8.3	0.201	14	(42.4)	19	(57.6)	0.661
10–19	113	12.6 ± 7.8		50	(44.2)	63	(55.8)
20–29	89	11.5 ± 7.6		46	(51.7)	43	(48.3)
≥ 30	64	12.0 ± 6.9		28	(43.8)	36	(56.3)
Severity of psoriasis (BSA)
Mild (< 5%)	146	10.5 ± 6.9	< 0.001	80	(54.8)	66	(45.2)	0.005
Moderate (5–9%)	65	13.0 ± 7.6		29	(44.6)	36	(55.4)
Severe (≥10%)	88	15.0 ± 8.0		29	(33.0)	59	(67.0)
Site of psoriasis
Head	233	13.0 ± 7.8	0.010	101	(43.3)	132	(56.7)	0.067
Face	141	14.4 ± 8.2	< 0.001	54	(38.3)	87	(61.7)	0.010
Neck	82	16.0 ± 7.5	< 0.001	21	(25.6)	61	(74.4)	< 0.001
Shoulder	115	15.2 ± 7.8	< 0.001	41	(35.7)	74	(64.3)	0.004
Chest/abdomen	191	13.5 ± 7.6	0.001	74	(38.7)	117	(61.3)	0.001
Back/buttocks	232	13.5 ± 7.7	< 0.001	93	(40.1)	139	(59.9)	< 0.001
Arm	229	13.2 ± 7.8	0.001	97	(42.4)	132	(57.6)	0.017
Hand	141	14.2 ± 7.7	< 0.001	51	(36.2)	90	(63.8)	0.001
Leg	263	12.4 ± 7.7	0.916	120	(45.6)	143	(54.4)	0.622
Foot	128	14.7 ± 7.6	< 0.001	43	(33.6)	85	(66.4)	< 0.001
Treatment for psoriasis
Topical treatment	246	12.8 ± 7.6	0.048	107	(43.5)	139	(56.5)	0.047
Prescribed oral medication	135	14.8 ± 7.9	< 0.001	44	(32.6)	91	(67.4)	< 0.001
Herbal medication	88	14.2 ± 7.8	0.009	30	(34.1)	58	(65.9)	0.007
Phototherapy	142	13.8 ± 8.1	0.002	57	(40.1)	85	(59.9)	0.047
Injections except biologics	45	15.1 ± 8.6	0.011	16	(35.6)	29	(64.4)	0.122
Biological therapy	28	11.8 ± 8.9	0.636	14	(50.0)	14	(50.0)	0.668

ISSN: 1477-7525